Press Releases

and/or
567 News Releases found
MSK Awards & Appointments October 2022
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:
Carol Morris, MD, MS
Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).
Left to right: Eileen M. O'Reilly, MD, Christine A. Iacobuzio-Donahue, MD, PhD
Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the National Cancer Institute (NCI).
Sloan Kettering Institute’s Alexander Gitlin
Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award.
MSK Awards & Appointments September 2022
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute, and Roswell Park Comprehensive Cancer Center report in a new study.
Memorial Sloan Kettering Cancer Center (MSK) is marking a year since the launch of MSK Telemedicine – an online solution for remote care that has been ...
Francesca Gany
The funding will support patient navigation, essential needs, telemedicine, and psychosocial support services, including language translation and interpretation.
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has joined the institution as President and Chief Executive Officer.
Jonathan E. Rosenberg, MD
Nearly two thirds of patients who were treated with the combination enfortumab vedotin plus pembrolizumab saw their tumors shrink.